Cognition Therapeutics Statistics
Total Valuation
CGTX has a market cap or net worth of $25.76 million. The enterprise value is $1.57 million.
Important Dates
The last earnings date was Thursday, March 20, 2025, before market open.
| Earnings Date | Mar 20, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
CGTX has 61.97 million shares outstanding. The number of shares has increased by 32.31% in one year.
| Current Share Class | 61.97M |
| Shares Outstanding | 61.97M |
| Shares Change (YoY) | +32.31% |
| Shares Change (QoQ) | +10.54% |
| Owned by Insiders (%) | 0.56% |
| Owned by Institutions (%) | 8.24% |
| Float | 55.63M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.33 |
| P/TBV Ratio | 1.37 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.65, with a Debt / Equity ratio of 0.04.
| Current Ratio | 2.65 |
| Quick Ratio | 2.49 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2,158.64 |
Financial Efficiency
Return on equity (ROE) is -157.19% and return on invested capital (ROIC) is -148.99%.
| Return on Equity (ROE) | -157.19% |
| Return on Assets (ROA) | -103.15% |
| Return on Invested Capital (ROIC) | -148.99% |
| Return on Capital Employed (ROCE) | -282.66% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.21M |
| Employee Count | 28 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -77.16% in the last 52 weeks. The beta is 1.03, so CGTX's price volatility has been similar to the market average.
| Beta (5Y) | 1.03 |
| 52-Week Price Change | -77.16% |
| 50-Day Moving Average | 0.56 |
| 200-Day Moving Average | 0.79 |
| Relative Strength Index (RSI) | 38.37 |
| Average Volume (20 Days) | 661,882 |
Short Selling Information
The latest short interest is 1.42 million, so 2.29% of the outstanding shares have been sold short.
| Short Interest | 1.42M |
| Short Previous Month | 2.11M |
| Short % of Shares Out | 2.29% |
| Short % of Float | 2.55% |
| Short Ratio (days to cover) | 0.50 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -53.97M |
| Pretax Income | -31.08M |
| Net Income | -33.97M |
| EBITDA | -53.86M |
| EBIT | -53.97M |
| Earnings Per Share (EPS) | -$0.86 |
Full Income StatementBalance Sheet
The company has $25.01 million in cash and $814,000 in debt, giving a net cash position of $24.20 million or $0.39 per share.
| Cash & Cash Equivalents | 25.01M |
| Total Debt | 814,000 |
| Net Cash | 24.20M |
| Net Cash Per Share | $0.39 |
| Equity (Book Value) | 18.75M |
| Book Value Per Share | 0.31 |
| Working Capital | 18.41M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$28.47 million and capital expenditures -$4,000, giving a free cash flow of -$28.48 million.
| Operating Cash Flow | -28.47M |
| Capital Expenditures | -4,000 |
| Free Cash Flow | -28.48M |
| FCF Per Share | -$0.46 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |